Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AIFF Stock Forecast 2026-2027
$1.15
Current Price
$17.95M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to AIFF Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
AIFF Price Momentum
-5.7%
1 Week Change
-24.3%
1 Month Change
-58.2%
1 Year Change
+30.7%
Year-to-Date Change
-68.3%
From 52W High of $3.63
+85.5%
From 52W Low of $0.62
📊 TOP ANALYST CALLS
Did AIFF Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Firefly is one of their latest high-conviction picks.
Latest AIFF Stock Price Targets & Analyst Predictions
AIFF has shown a year-to-date change of 30.7% and a 1-year change of -58.2%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for AIFF. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AIFF Analyst Ratings
0
Buy
0
Hold
0
Sell
AIFF Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $1.15
Latest AIFF Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AIFF.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Firefly Neuroscience Inc. (AIFF) Competitors
The following stocks are similar to Firefly based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Firefly Neuroscience Inc. (AIFF) Financial Data
Firefly Neuroscience Inc. has a market capitalization of $17.95M with a P/E ratio of -0.6x. The company generates $1.58M in trailing twelve-month revenue with a 56.5% profit margin.
Revenue growth is +1,027.9% quarter-over-quarter, while maintaining an operating margin of -414.4% and return on equity of -131.4%.
Valuation Metrics
Market Cap
$17.95M
Enterprise Value
$14.78M
P/E Ratio
-0.6x
PEG Ratio
0.0x
Price/Sales
11.3x
Growth & Margins
Revenue Growth (YoY)
+1,027.9%
Gross Margin
+45.6%
Operating Margin
-414.4%
Net Margin
+56.5%
EPS Growth
+1,027.9%
Financial Health
Cash/Price Ratio
+17.5%
Current Ratio
1.8x
Debt/Equity
0.0x
ROE
-131.4%
ROA
-45.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Firefly Neuroscience Inc. (AIFF) Business Model
About Firefly Neuroscience Inc.
What They Do
Develops AI-driven solutions for brain health.
Business Model
The company generates revenue by providing its FDA-cleared Brain Network Analytics (BNA™) platform and CLEAR Platform to pharmaceutical companies, medical technology firms, and clinical practitioners. These products help analyze EEG and ERP data for better diagnosis and treatment of neurological disorders, thus supporting drug research and clinical trials.
Additional Information
Founded in 2006 and based in Kenmore, New York, Firefly Neuroscience Inc. focuses on advancing brain health outcomes through collaborations with academic institutions and partners in neuroscience research. The company primarily operates in North America and is committed to enhancing the quality of EEG data analysis.
Company Information
Sector
Technology
Industry
Software - Application
Employees
17
CEO
Mr. Greg Lipschitz
Country
United States
IPO Year
2024
Website
fireflyneuro.comFirefly Neuroscience Inc. (AIFF) Latest News & Analysis
Latest News
Firefly's AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD
1 month ago
Quick Summary
Firefly Neuroscience (NASDAQ: AIFF) identified a new biomarker for PTSD using its FDA-cleared Evoke System, following its partnership with the U.S. Department of War to aid service members and veterans.
Why It Matters
Firefly's biomarker discovery for PTSD enhances its value in the healthcare sector, particularly with military applications, potentially increasing demand and investor interest in its technology.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Firefly's total brain scan volumes have shown sequential growth, increasing by higher percentages for four consecutive quarters.
Why It Matters
Rising brain scan volumes indicate growing demand for Firefly's services, suggesting potential revenue growth and improved market positioning, which can enhance investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Firefly's AI-driven EEG/ERP technology, cleared by the FDA, is being used to assess and treat PTSD and TBI in U.S. service members.
Why It Matters
Firefly's FDA clearance and deployment of AI technology for PTSD and TBI treatment may enhance its market position, attract investment, and drive future revenue growth in the healthcare sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD
4 months ago
Quick Summary
Over 22 million Americans have ADHD, but no objective biological marker exists to differentiate its three subtypes.
Why It Matters
The lack of a biological marker for ADHD subtypes affects research and treatment development, impacting pharmaceutical stocks and investment in mental health solutions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Firefly Neuroscience Inc. (NASDAQ: AIFF) shares rose on Friday amid progress in developing brain scan technologies.
Why It Matters
Firefly Neuroscience's advancements in brain scan technologies suggest potential growth and innovation, likely boosting investor confidence and driving share prices higher.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Firefly Neuroscience Inc. (NASDAQ: AIFF) shares increased on Wednesday as the company advances its human brain foundation model development.
Why It Matters
Firefly Neuroscience's share price increase indicates growing investor confidence in its innovative brain model, which could signal future revenue potential and market leadership in neuroscience.
Source: Benzinga
Market Sentiment:
Positive
Frequently Asked Questions About AIFF Stock
What is Firefly Neuroscience Inc.'s (AIFF) stock forecast for 2027?
Analyst forecasts for Firefly Neuroscience Inc. (AIFF) are not currently available. The stock is trading at $1.15.
Is AIFF stock a good investment in 2027?
Analyst ratings for AIFF are not currently available. The stock is currently trading at $1.15. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AIFF stock?
Price predictions from Wall Street analysts for AIFF are not currently available. The stock is trading at $1.15.
What is Firefly Neuroscience Inc.'s business model?
The company generates revenue by providing its FDA-cleared Brain Network Analytics (BNA™) platform and CLEAR Platform to pharmaceutical companies, medical technology firms, and clinical practitioners. These products help analyze EEG and ERP data for better diagnosis and treatment of neurological disorders, thus supporting drug research and clinical trials.
What is the highest forecasted price for AIFF Firefly Neuroscience Inc.?
Price targets from Wall Street analysts for AIFF are not currently available. The stock is trading at $1.15.
What is the lowest forecasted price for AIFF Firefly Neuroscience Inc.?
Price targets from Wall Street analysts for AIFF are not currently available. The stock is trading at $1.15.
What is the overall AIFF consensus from analysts for Firefly Neuroscience Inc.?
Analyst ratings for AIFF are not currently available. The stock is trading at $1.15.
How accurate are AIFF stock price projections?
Stock price projections, including those for Firefly Neuroscience Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 6:47 PM UTC